Breast CancerPhase 3IPATunity130NCT03337724
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
A Phase 3 study testing Ipatasertib and Paclitaxel in people with Breast Cancer, run by Hoffmann-La Roche at 176 sites in 30 countries.
Trial summary
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Ipatasertib and Paclitaxel
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 579 participants
- Where
- 176 sitesin 30 countries
- Study dates
- 6 Jan 2018to 4 Jan 2023
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women or men aged =>18 years with histologically documented triple-negative breast cancer (TNBC) or HR+/HER2- adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate hematologic and organ function within 14 days prior to treatment initiation
- Histologically documented TNBC or HR+/HER2- adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Eligible for taxane monotherapy, as per local investigator assessment (e.g., absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control which may require combination chemotherapy)
Show all 11Show fewer
- HR+/HER2- breast cancer that is not considered appropriate for endocrine-based therapy and meets one of the following: patient has recurrent disease <=5 years of being on adjuvant endocrine therapy or if patient with de novo metastatic disease have progressed within 6 months of being on first line endocrine therapy.
- Consent to submit a formalin-fixed, paraffin-embedded tumor (FFPE) tissue block or freshly cut unstained, serial tumor slides from the most recently collected tumor tissue for central molecular analysis
- Confirmation of biomarker eligibility using an appropriately validated molecular assay at a diagnostic laboratory, Clinically Laboratory Improvement Amendments (CLIA) or equivalently accredited i.e., valid results from either central testing or local testing of tumor tissue or blood demonstrating PIK3CA/AKT1/PTEN-altered status
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and agreement to refrain from donating sperm
Who cannot join
- Treatment with approved or investigational cancer therapy within 14 days prior to treatment initiation
- Any previous chemotherapy for inoperable locally advanced or metastatic TNBC or HR+/HER2- adenocarcinoma of the breast (patients receiving neo/adjuvant chemotherapy eligible provided they have at least a 12 month disease-free interval)
- History of or known presence of brain or spinal cord metastases
- Malignancies other than breast cancer within 5 years prior to treatment initiation (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)
- Prior treatment with an Akt inhibitor (prior PI3K or mTOR inhibitors are allowed)
- History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills
Show all 21Show fewer
- Active infection requiring systemic anti-microbial treatment (including antibiotics, anti-fungals, and anti-viral agents)
- Known human immunodeficiency virus (HIV) infection
- Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis, current drug or alcohol abuse, or cirrhosis
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of treatment (or anticipated need during study)
- Pregnant or breastfeeding, or intending to become pregnant during the study
- Clinically significant cardiac dysfunction (including NYHA Class II/III/IV heart failure, left ventricular ejection fraction [LVEF] <50%, active ventricular arrhythmia requiring medication, history of myocardial infarction within 6 months of treatment initiation, clinically significant electrocardiogram [ECG] abnormalities).
- Need for chronic corticosteroid therapy of >=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease
- Unresolved, clinically significant toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy
- Uncontrolled clinical symptoms including pleural effusion, pericardial effusion, or ascites, tumor-related pain, hypercalcemia (or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy)
- History of Type I or Type II diabetes mellitus requiring insulin
- Grade >=2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia
- History of or active inflammatory bowel disease or active bowel inflammation
- Clinically significant lung disease (including pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, active infection/ history of opportunistic infections)
- Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of treatment
- Grade >=2 peripheral neuropathy
Trial locations and contacts
176 sites in 30 countries.
176 sites in 30 countries
United States28 sites
University of Maryland
Baltimore, Maryland, 21201
Mercy Medical Center
Baltimore, Maryland, 21202
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287
Texas Oncology, P.A.
Dallas, Texas, 75246
UT Southwestern Medical Center; Simmons Comprehensive Cancer Center, Simmons Pharmacy
Dallas, Texas, 75390
West Clinic
Germantown, Tennessee, 38138
Memorial Sloan Kettering Cancer Center at Westchester
Harrison, New York, 10604
Memorial Regional Hospital
Hollywood, Florida, 33021
Oncology Consultants PA
Houston, Texas, 77030
UCSD Moores Cancer Center
La Jolla, California, 92093
USC Norris Cancer Center
Los Angeles, California, 90033
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140
Memorial Sloan Kettering
New York, New York, 10065
USC Norris Cancer Center; USC Oncology Hematology Newport Beach
Newport Beach, California, 92663
Kaiser Permanente - Oakland
Oakland, California, 94611
UF Health Cancer Center at Orlando Health
Orlando, Florida, 32824
Memorial Hospital West
Pembroke Pines, Florida, 33028
Kaiser Permanente - Roseville
Roseville, California, 95661
UC Davis; Comprehensive Cancer Center
Sacramento, California, 95817
Kaiser Permanente Sacramento Medical Center
Sacramento, California, 95825
Kaiser Permanente - San Francisco (2238 Geary)
San Francisco, California, 94115
UCSF Comprehensive Cancer Ctr
San Francisco, California, 94158
K. Permanente - San Jose
San Jose, California, 95119
Kaiser Permanente - San Leandro
San Leandro, California, 94577
K. Permanente - Santa Clara
Santa Clara, California, 95051
Kaiser Permanente - South San Francisco
South San Francisco, California, 94080
Kaiser Permanente - Vallejo
Vallejo, California, 94589
K. Permanente - Walnut Creek
Walnut Creek, California, 94596
Japan19 sites
Aichi Cancer Center Hospital
Aichi, 464-8681
National Cancer Center Hospital East
Chiba, 277-8577
National Hospital Organization Kyushu Cancer Center;Breast Oncology
Fukuoka, 811-1395
Fukushima Medical University Hospital
Fukushima, 960-1295
Hyogo Medical University Hospital
Hyōgo, 663-8501
St. Marianna University Hospital
Kanagawa, 216-8511
Kanagawa Cancer Center
Kanagawa, 241-8515
Tokai University Hospital
Kanagawa, 259-1193
Kumamoto Shinto General Hospital
Kumamoto, 862-8655
Niigata Cancer Center Hospital
Niigata, 951-8566
Okayama University Hospital
Okayama, 700-8558
National Hospital Organization Osaka National Hospital
Osaka, 540-0006
Kinki University Hospital, Faculty of Medicine; Surgery
Osaka, 589-8511
Saitama Cancer Center, Breast Oncology
Saitama, 362-0806
Shizuoka Cancer Center
Shizuoka, 411-8777
National Cancer Center Hospital
Tokyo, 104-0045
St. Luke's International Hospital
Tokyo, 104-8560
The Cancer Institute Hospital of JFCR
Tokyo, 135-8550
Showa University Hospital; Breast Surgery
Tokyo, 142-8666
Spain12 sites
Hospital del Mar; Servicio de Oncologia
Barcelona, 08003
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035
Hospital Clinic Barcelona; Servicio de oncologia
Barcelona, 08036
Hospital Provincial de Castellon; Servicio de Oncologia
Castellon, Castellon, 12002
Hospital Universitario Reina Sofia; Servicio de Oncologia
Córdoba, Cordoba, 14004
Hospital de Donostia; Servicio de Oncologia
Guipuzcoa, Guipuzcoa, 20014
Hospital Ramon y Cajal; Servicio de Oncologia
Madrid, 28034
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia
Madrid, 28050
Hospital Universitario Puerta de Hierro; Servicio de Oncologia
Majadahonda, Madrid, 28222
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
Santiago de Compostela, LA Coruña, 15706
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
Seville, 41013
Hospital Clinico Universitario; Oncologia
Valencia, 46010
Germany10 sites
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, 10707
Praxis Dr.med. Katja Ziegler-Löhr
Cologne, 50679
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
Freiburg im Breisgau, 79110
Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
Hamburg, 20246
Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe
Homburg/Saar, 66424
Dres. Andreas Köhler und Roswitha Fuchs
Langen, 63225
Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Frauenheilkunde und Geburtshilfe
Minden, 32429
Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie
Recklinghausen, 45659
Universitätsfrauen- und Poliklinik am Klinikum Suedstadt
Rostock, 18059
Universitätsklinikum Würzburg; Frauenklinik
Würzburg, 97080
Russia9 sites
Arkhangelsk Regional Clinical Oncology Dispensary
Arkhangelsk, Arhangelsk, 163045
Ivanovo Regional Oncology Dispensary
Ivanovo, 153040
SBIH Kaluga Region Clinical Oncology Dispensary
Kaluga, 248007
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
Kazan', Tatarstan Republic, 420029
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moscow Oblast, 143423
Federal State Institution, Moscow Research Oncology Institute n.a. P.A. Hertzen; Oncourology
Moscow, Moscow Oblast, 125284
Blokhin Cancer Research Center; Combined Treatment
Moskva, Moscow Oblast, 115478
FSI Rostov research oncological institute of MoH and SD of RF; PAD
Rostov-on-Don, Rostov Oblast, 344037
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
Saint Petersburg, Sankt-Peterburg, 197758
Brazil8 sites
Hospital Araujo Jorge; Departamento de Ginecologia E Mama
Goiânia, Goiás, 74605-070
Hospital do Câncer de Londrina
Londrina, Paraná, 86015-520
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 91350-200
Instituto Nacional de Cancer - INCa; Oncologia
Rio de Janeiro, Rio de Janeiro, 20560-120
Santa Casa de Misericordia de Salvador
Salvador, Estado de Bahia, 40050-410
Faculdade de Medicina do ABC - FMABC
Santo André, São Paulo, 09060-650
Hospital Perola Byington
São Paulo, São Paulo, 01317-000
Peru8 sites
Centro Medico Monte Carmelo
Arequipa, 04001
Hospital Daniel Alcides Carrion
Callao, 07021
Clínica San Gabriel; Unidad de Investigación Oncológica de la Clínica San Gabriel
Lima, 15088
Hospital Nacional Cayetano Heredia; Ocología; Servicio de Hematología Oncología Médica
Lima, 15102
Oncosalud Sac; Oncología
Lima, 41
Instituto Nacional de Enfermedades Neoplasicas
Lima, Lima 34
Clinica Ricardo Palma
San Isidro, Lima 27
Instituto Regional de Enfermedades Neoplasicas - IREN Norte
Trujillo, 13014
France7 sites
CHU Besançon - Hôpital Jean Minjoz
Besançon, 25030
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, 33300
Centre Georges Francois Leclerc; Oncologie 3
Dijon, 21079
ICM; Medecine B3
Montpellier, 34298
Centre Catherine De Sienne
Nantes, 44202
APHP - Hospital Saint Louis
Paris, 75475
Institut Jean Godinot; Oncologie Medicale
Reims, 51056
South Korea7 sites
National Cancer Center
Goyang-si, 10408
Inha University Hospital
Incheon, 22332
Seoul National University Bundang Hospital
Seongnam-si, 463-707
Seoul National University Hospital
Seoul, 03080
Severance Hospital, Yonsei University Health System
Seoul, 03722
Asan Medical Center
Seoul, 05505
Samsung Medical Center
Seoul, 06351
United Kingdom7 sites
Velindre Cancer Centre
Cardiff, CF14 2TL
University Hospital coventry; Oncology Department
Coventry, CV2 2DX
The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit
Glasgow, G12 0YN
Royal Marsden Hospital - London
London, SW3 6JJ
Derriford Hospital
Plymouth, PL6 8BT
Royal Stoke University Hospital
Stoke-on-Trent, ST4 6QG
Royal Marsden Hospital; Dept of Medical Oncology
Sutton, SM2 5PT
Australia6 sites
Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit
Bull Creek, Western Australia, 6149
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050
Cabrini Medical Centre; Oncology
Malvern, Victoria, 3144
Mater Hospital; Cancer Services
South Brisbane, Queensland, 4101
Calvary Mater Newcastle; Medical Oncology
Waratah, New South Wales, 2298
Westmead Hospital; Medical Oncology
Wentworthville, New South Wales, 2145
Turkey (Türkiye)6 sites
Ankara Bilkent City Hospital
Ankara, 06490
Dicle Uni Medical Faculty; Internal Medicine
Diyarbakır, 10000
Medipol University Medical Faculty; Oncology Department
Istanbul, 34214
Prof. Dr. Cemil Tascioglu City Hospital; Med Onc
Istanbul, 34384
Katip Celebi University Ataturk Training and Research Hospital; Oncology
Izmir, 35360
Sakarya University Medical School; Medical Oncology
Sakarya, 54100
Hungary5 sites
Orszagos Onkologial Intezet; Onkologiai Osztaly X
Budapest, 1122
Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly
Miskolc, 3501
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
Szeged, 6720
Hetenyi Geza County Hospital; Onkologiai Kozpont
Szolnok, 5004
Zala County Hospital ICU
Zalaegerszeg, 8900
Italy5 sites
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
Aviano, Friuli Venezia Giulia, 33081
Ospedale Santa Maria Annunziata; Oncologia
Bagno a Ripoli, Tuscany, 50012
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
Bologna, Emilia-Romagna, 40138
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica
Naples, Campania, 80131
IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
Padova, Veneto, 35128
Mexico4 sites
Merida | Investigacion Clinica
Mérida, Yucatán, 97125
Centro Medico Dalinde
Mexico City, Mexico CITY (federal District), 06760
CENEIT Oncologicos; DENTRO DE CONDOMINIO SAN FRANCISCO
Mexico City, 03100
Centro Médico Zambrano Hellion
Monterrey, Nuevo León, 66278
Taiwan4 sites
Chi Mei Medical Center Liou Ying Campus
Liuying Township, 736
VETERANS GENERAL HOSPITAL; Department of General Surgery
Taipei, 00112
National Taiwan Uni Hospital; General Surgery
Taipei, 100
Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
Taipei, 11259
Ukraine4 sites
Chemotherapy SI Dnipropetrovsk MA of MOHU
Dnipropetrovsk, 49102
Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients
Kiev, 03115
National Cancer Institute MOH of Ukraine
Kiev, 36022
Lviv State Oncological Regional Treatment and Diagnostic Center
Lviv, 79031
Belgium3 sites
Cliniques Universitaires St-Luc
Brussels, 1200
GHdC Site Notre Dame
Charleroi, 6000
UZ Leuven Gasthuisberg
Leuven, 3000
Greece3 sites
Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine
Athens, 115 22
Agioi Anargyroi; 3Rd Dept. of Medical Oncology
Athens, 145 64
Euromedical General Clinic of Thessaloniki; Oncology Department
Thessaloniki, 546 45
North Macedonia3 sites
Clinical Hospital; Oncology Department
Bitola, 7000
PHI University Clinic of Radiotherapy and Oncology; Breast malignancy
Skopje, 1000
PHI University Clinic of Radiotherapy and Oncology; Malignant diseases of thorax
Skopje, 1000
Poland3 sites
Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chorób Piersi z Podod. Onko Klinicznej
?ód?, 93-338
Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; III Klin. Radioter. i Chemioter.
Gliwice, 44-101
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr
Warsaw, 02-781
Argentina2 sites
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, C1125ABD
Hosp Provincial D. Centenarios; Oncology Dept
Rosario, S2002KDS
Canada2 sites
Jewish General Hospital
Montreal, Quebec, H3T 1E2
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
Costa Rica2 sites
Clinica CIMCA
San José, 10103
ICIMED Instituto de Investigación en Ciencias Médicas
San José, 10108
Czechia2 sites
Masaryk?v onkologický ústav; Klinika komplexní onkologické pé?e
Brno, 656 53
Fakultni nemocnice Olomouc; Onkologicka klinika
Olomouc, 779 00
India2 sites
Indraprastha Apollo Hospitals
New Delhi, National Capital Territory of Delhi, 110076
Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology
New Delhi, National Capital Territory of Delhi, 110085
Singapore2 sites
National University Hospital; National University Cancer Institute, Singapore (NCIS)
Singapore, 119228
National Cancer Centre; Medical Oncology
Singapore, 168583
South Africa1 site
Medical Oncology Centre of Rosebank; Oncology
Johannesburg, 2196
About this study
Official title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) breast adenocarcinoma who are not suitable for endocrine therapy.
- Conditions
- Breast Cancer
- Being tested
- Ipatasertib, Paclitaxel, Placebo
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IpatasertibDrug
Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
PaclitaxelDrug
Paclitaxel, 80 mg/square meter (m^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
PlaceboDrug
Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
| Study group | Role | What they receive |
|---|---|---|
| Ipatasertib + Paclitaxel | Experimental | Not described Receives: Drug: Ipatasertib; Drug: Paclitaxel |
| Placebo + Paclitaxel | Experimental | Not described Receives: Drug: Paclitaxel; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cohort A: Progression-Free Survival (PFS)
PFS was defined as the time from randomization to the first occurrence of disease progression, as determined locally by the investigator through the use of Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1), or death from any cause, whichever occurred first, assessed up to 27 months for this outcome measure. Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression.
Measured: From randomization up to 27 months
Cohort B: PFS
PFS was defined as the time from randomization to the first occurrence of disease progression, as determined locally by the investigator through the use of RECIST v.1.1, or death from any cause, whichever occurred first, assessed up to 24.4 months for this outcome measure. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. Abbreviation used in statistical analysis: PI3K=phosphoinositide 3-kinase and mTOR=mammalian target of rapamycin inhibitor.
Measured: From randomization up to 24.4 months
Cohort C: PFS
PFS for Cohort C was defined as the time from enrollment to the first occurrence of disease progression, as determined locally by the investigator through the use of RECIST v.1.1, or death from any cause, whichever occurred first, assessed up to 31 months for this outcome measure. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Measured: From enrollment up to 31 months
Secondary outcomes (20)
Cohort A and B: Objective Response Rate (ORR)
ORR was defined as percentage of participants with partial response (PR) or complete response (CR) on 2 consecutive occasions ≥4 weeks apart as determined by the investigator using RECIST v.1.1, assessed up to 27 months for Cohort A and up to 24.4 months for Cohort B, for this outcome measure. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Percentages are rounded off to the nearest decimal point.
Measured: From randomization up to 27 months for Cohort A and up to 24.4 months for Cohort B
Cohort C: ORR
ORR was defined as percentage of participants with PR or CR on 2 consecutive occasions ≥4 weeks apart as determined by the investigator using RECIST v.1.1, assessed up to 31 months for this outcome measure. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Percentages are rounded off to the nearest decimal point.
Measured: From enrollment up to 31 months
Cohort A and B: Duration of Response (DOR)
DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD, as determined locally by the investigator through the use of RECIST v1.1, or death from any cause, whichever occurred first assessed up to 27 months for Cohort A and up to 24.4 months for Cohort B, for this outcome measure. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Measured: From randomization up to 27 months for Cohort A and up to 24.4 months for Cohort B
Cohort C: DOR
DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD, as determined locally by the investigator through the use of RECIST v1.1, or death from any cause, whichever occurred first, assessed up to 31 months for this outcome measure. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Measured: From enrollment up to 31 months
Cohort A and B: Clinical Benefit Rate (CBR)
CBR was defined as percentage of participants with an objective response (CR or PR), or stable disease (SD) for at least 24 weeks, as determined by the investigator through the use of RECIST v.1.1. assessed up to From randomization up to 27 months for Cohort A and up to 24.4 months for Cohort B for this outcome measure. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Percentages are rounded off to the nearest decimal point.
Measured: From randomization up to 27 months for Cohort A and up to 24.4 months for Cohort B
Cohort C: CBR
CBR was defined as percentage of participants with an objective response (CR or PR), or SD for at least 24 weeks, as determined by the investigator through the use of RECIST v.1.1 assessed up to 31 months for this outcome measure. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Percentages are rounded off to the nearest decimal point.
Measured: From enrollment up to 31 months
Overall Survival (OS)
OS was defined as the time from randomization to death from any cause.
Measured: From randomization/ enrollment (Cohort C) up to death from any cause, up to 45 months for Cohort A, up to 46 months for Cohort B and up to 31 months for Cohort C
Cohort A and B: Change From Baseline in Global Health Status (GHS)/Health-Related Quality of Life (HRQoL) Score Measured by GHS/HRQoL Scale (Questions 29 and 30) of the EORTC QLQ-C30
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is a cancer-specific instrument with 30 questions covering symptoms, functioning, and health-related quality of life (HRQoL). The participant's assessment of overall HRQoL is assessed by using the last 2 questions (29 and 30) of the instrument, with each of these items based on a 7-point scale (1=very poor to 7=excellent), which are then combined into the GHS/QoL multi-item scale. The scores obtained for each question were averaged into a raw score for the scale, and this raw score for the scale was then subsequently linearly transformed to a scale score of 0 to 100, with a high score indicating better GHS/QoL. Negative change from Baseline values in the GHS/QoL change from baseline analysis indicated deterioration in HRQoL and positive values indicated improvement.
Measured: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 (cycle length=28 days)
Cohort C: Change From Baseline in GHS/HRQoL Score Measured by GHS/HRQoL Scale (Questions 29 and 30) of the EORTC QLQ-C30
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions covering symptoms, functioning, and health-related quality of life (HRQoL). The participant's assessment of overall HRQoL is assessed by using the last 2 questions (29 and 30) of the instrument, with each of these items based on a 7-point scale (1=very poor to 7=excellent), which are then combined into the GHS/QoL multi-item scale. The scores obtained for each question were averaged into a raw score for the scale, and this raw score for the scale was then subsequently linearly transformed to a scale score of 0 to 100, with a high score indicating better GHS/QoL. Negative change from Baseline values in the GHS/QoL change from baseline analysis indicated deterioration in HRQoL and positive values indicated improvement.
Measured: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, and 44 (cycle length=28 days)
Cohort B: Time to Deterioration (TTD) in Pain
Time to deterioration in GHS/HRQoL was defined as the time from randomization to first observed ≥ 11-point increase from Baseline in pain scale score (Question 9 and 19) in EORTC QLQ-C30 linearly transformed GHS/HRQoL scale score, assessed up 24.4 months for this outcome measure. TTD was planned to be assessed only in cohort with HR+/HER2 - breast cancer participants (Cohort B). Questions 9 and 19 that assessed pain, used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). The scores were linearly transformed on a scale of 0 to 100, with higher scores indicating increased severity in symptoms.
Measured: Baseline up to 24.4 months
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0.
Measured: Up to 58.9 months for Cohort A, up to 59.9 months for Cohort B and up to 45.5 months for Cohort C
Number of Participants With at Least One Adverse Events of Special Interest (AESI)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the NCI CTCAE, Version 4.0. AESI include cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law. Suspected transmission of an infectious agent by the study drug, Grade >= 3 fasting hyperglycemia, hepatotoxicity, diarrhea, rash, ALT/AST elevations. Grade >= 2 colitis/enterocolitis.
Measured: Up to 58.9 months for Cohort A, up to 59.9 months for Cohort B and up to 45.5 months for Cohort C
Cohorts A and B:Plasma Concentration of Ipatasertib
Measured: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days)
Cohort C: Plasma Concentration of Ipatasertib
Measured: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days)
Cohorts A and B: Plasma Concentration of G-037720
G-037720 was a metabolite of ipatasertib.
Measured: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days )
Cohort C: Plasma Concentration of G-037720
G-037720 was a metabolite of ipatasertib.
Measured: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days )
Cohort C: 1-year Event-free PFS Rate
PFS was defined as the time from enrollment to the first occurrence of disease progression, as determined locally by the investigator through the use of RECIST v.1.1, or death from any cause, whichever occurred first. Event-free PFS rate was defined as percentage of participants who did not experience any event and survived at 1 year after enrollment. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. Percentages are rounded off to the nearest decimal point. As prespecified in the protocol, this outcome measure was applicable only to Cohort C.
Measured: From enrollment until the occurrence of disease progression or death from any cause, whichever occurred earlier, up to 1 year
Cohort C: 1-year Event-free OS Rate
OS was defined as the time from enrollment to death from any cause. Event-free OS rate was defined as percentage of participants who did not experience any event and survived at 1 year after enrollment. As prespecified in the protocol, this outcome measure was applicable only to Cohort C. Percentages were rounded off to the nearest decimal.
Measured: From enrollment up to death from any cause, up to 1 year
Cohort C: Serum Concentration of Atezolizumab
As prespecified in the protocol, this outcome measure was applicable only to Cohort C.
Measured: Day 1 of Cycle 1: 30 minutes post dose, predose on Day 15 of Cycle 1 and predose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length=28 days)
Cohort C: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
The numbers of ADA-positive participants after drug administration were summarized for participants exposed to atezolizumab. As prespecified in the protocol, this outcome measure was applicable only to Cohort C.
Measured: Up to 45.5 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2017
- Study start6 Jan 2018
- Primary completion4 Jan 2023
- Study completion4 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 579 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03337724
- Sponsor's protocol ID
- CO40016
- Other IDs
- 2017-001548-36, 2017
- Acronym
- IPATunity130
- Status last verified
- Feb 2024
- First submitted
- 7 Nov 2017
- Last updated
- 12 Mar 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022 Feb;191(3):565-576. doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 3.
PubMed 34860318
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
- ClinicalTrials.gov ID
- NCT03337724
- Acronym / sponsor ID
- IPATunity130 / CO40016
- Conditions
- Breast Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 579 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 6 Jan 2018 (actual)
- Primary completion
- 4 Jan 2023 (actual)
- Study completion
- 4 Jan 2023 (actual)
- First posted
- 9 Nov 2017 (actual)
- Results
- Posted 12 Mar 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) breast adenocarcinoma who are not suitable for endocrine therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ipatasertib + Paclitaxel | Experimental | Drug: Ipatasertib, Drug: Paclitaxel |
| Placebo + Paclitaxel | Experimental | Drug: Paclitaxel, Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Women or men aged =>18 years with histologically documented triple-negative breast cancer (TNBC) or HR+/HER2- adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate hematologic and organ function within 14 days prior to treatment initiation
- Histologically documented TNBC or HR+/HER2- adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to resection with curative intent
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Key exclusion criteria (21 listed)
- Treatment with approved or investigational cancer therapy within 14 days prior to treatment initiation
- Any previous chemotherapy for inoperable locally advanced or metastatic TNBC or HR+/HER2- adenocarcinoma of the breast (patients receiving neo/adjuvant chemotherapy eligible provided they have at least a 12 month disease-free interval)
- History of or known presence of brain or spinal cord metastases
- Malignancies other than breast cancer within 5 years prior to treatment initiation (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)
- Prior treatment with an Akt inhibitor (prior PI3K or mTOR inhibitors are allowed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IpatasertibIpatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination. | Drug | Ipatasertib + Paclitaxel |
| PaclitaxelPaclitaxel, 80 mg/square meter (m^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination. | Drug | Ipatasertib + Paclitaxel, Placebo + Paclitaxel |
| PlaceboMatching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination. | Drug | Placebo + Paclitaxel |
Primary outcome
Cohort A: Progression-Free Survival (PFS)
Time frame: From randomization up to 27 months
PFS was defined as the time from randomization to the first occurrence of disease progression, as determined locally by the investigator through the use of Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1), or death from any cause, whichever occurred first, assessed up to 27 months for this outcome measure. Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression.
Cohort B: PFS
Time frame: From randomization up to 24.4 months
PFS was defined as the time from randomization to the first occurrence of disease progression, as determined locally by the investigator through the use of RECIST v.1.1, or death from any cause, whichever occurred first, assessed up to 24.4 months for this outcome measure. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression. Abbreviation used in statistical analysis: PI3K=phosphoinositide 3-kinase and mTOR=mammalian target of rapamycin inhibitor.
Cohort C: PFS
Time frame: From enrollment up to 31 months
PFS for Cohort C was defined as the time from enrollment to the first occurrence of disease progression, as determined locally by the investigator through the use of RECIST v.1.1, or death from any cause, whichever occurred first, assessed up to 31 months for this outcome measure. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
20 secondary outcomes
Cohort A and B: Objective Response Rate (ORR)
Time frame: From randomization up to 27 months for Cohort A and up to 24.4 months for Cohort B
Cohort C: ORR
Time frame: From enrollment up to 31 months
Cohort A and B: Duration of Response (DOR)
Time frame: From randomization up to 27 months for Cohort A and up to 24.4 months for Cohort B
Cohort C: DOR
Time frame: From enrollment up to 31 months
Cohort A and B: Clinical Benefit Rate (CBR)
Time frame: From randomization up to 27 months for Cohort A and up to 24.4 months for Cohort B
Cohort C: CBR
Time frame: From enrollment up to 31 months
Overall Survival (OS)
Time frame: From randomization/ enrollment (Cohort C) up to death from any cause, up to 45 months for Cohort A, up to 46 months for Cohort B and up to 31 months for Cohort C
Cohort A and B: Change From Baseline in Global Health Status (GHS)/Health-Related Quality of Life (HRQoL) Score Measured by GHS/HRQoL Scale (Questions 29 and 30) of the EORTC QLQ-C30
Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 (cycle length=28 days)
Cohort C: Change From Baseline in GHS/HRQoL Score Measured by GHS/HRQoL Scale (Questions 29 and 30) of the EORTC QLQ-C30
Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, and 44 (cycle length=28 days)
Cohort B: Time to Deterioration (TTD) in Pain
Time frame: Baseline up to 24.4 months
Number of Participants With Adverse Events (AEs)
Time frame: Up to 58.9 months for Cohort A, up to 59.9 months for Cohort B and up to 45.5 months for Cohort C
Number of Participants With at Least One Adverse Events of Special Interest (AESI)
Time frame: Up to 58.9 months for Cohort A, up to 59.9 months for Cohort B and up to 45.5 months for Cohort C
Cohorts A and B:Plasma Concentration of Ipatasertib
Time frame: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days)
Cohort C: Plasma Concentration of Ipatasertib
Time frame: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days)
Cohorts A and B: Plasma Concentration of G-037720
Time frame: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days )
Cohort C: Plasma Concentration of G-037720
Time frame: Days 1 and 15 of Cycle 1: 1 to 3 hours post dose, and on Day 15 of Cycle 3: 2 to 4 hours post dose (cycle length= 28 days )
Cohort C: 1-year Event-free PFS Rate
Time frame: From enrollment until the occurrence of disease progression or death from any cause, whichever occurred earlier, up to 1 year
Cohort C: 1-year Event-free OS Rate
Time frame: From enrollment up to death from any cause, up to 1 year
Cohort C: Serum Concentration of Atezolizumab
Time frame: Day 1 of Cycle 1: 30 minutes post dose, predose on Day 15 of Cycle 1 and predose on Day 1 of Cycles 2, 3, 4, 8, 12 and 16 (cycle length=28 days)
Cohort C: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Time frame: Up to 45.5 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 34860318Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022 Feb;191(3):565-576. doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 3.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
176 sites in 30 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ipatasertib and Paclitaxel in people with Breast Cancer, run by Hoffmann-La Roche at 176 sites in 30 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 176 sites in United States, Japan, Spain, Germany, Russia and 25 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Mar 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cohort A: Progression-Free Survival (PFS) (time frame: From randomization up to 27 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03337724, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2024.